Search research articles
Contact Us
Filters
Showing results (1-10 of 36) with videos related to
Page
of 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 23, 2015
Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials
Will Garner, Kirsten White, Javier Szwarcberg, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
April 9, 2018
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks
Nicolas Margot, Stephanie Cox, Moupali Das, et al.
Antiviral Therapy
|
January 12, 2017
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Nicolas Margot, Stephanie Cox, Moupali Das, et al.
Journal of the International AIDS Society
|
December 21, 2019
Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
Robertino Mera, Susan Scheer, Christoph Carter, et al.
HIV Clinical Trials
|
February 1, 2005
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers
Thomas R MacGregor, John P Sabo, Stephen H Norris, et al.
HIV Clinical Trials
|
February 20, 2016
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Nicolas A Margot, Kathryn M Kitrinos, Marshall Fordyce, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2004
A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
Scott McCallister, Hernan Valdez, Kevin Curry, et al.
HIV Clinical Trials
|
April 20, 2010
Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients
Frank D Goebel, Thomas R MacGregor, John P Sabo, et al.
Antimicrobial Agents and Chemotherapy
|
November 24, 2005
Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers
Geoffrey Mukwaya, Thomas MacGregor, David Hoelscher, et al.
Plos One
|
December 12, 2019
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
Linn Hermansson, Aylin Yilmaz, Richard W Price, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 36) with videos related to
Sort By:
Page
of 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 23, 2015
Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials
Will Garner, Kirsten White, Javier Szwarcberg, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
April 9, 2018
Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks
Nicolas Margot, Stephanie Cox, Moupali Das, et al.
Antiviral Therapy
|
January 12, 2017
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Nicolas Margot, Stephanie Cox, Moupali Das, et al.
Journal of the International AIDS Society
|
December 21, 2019
Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
Robertino Mera, Susan Scheer, Christoph Carter, et al.
HIV Clinical Trials
|
February 1, 2005
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers
Thomas R MacGregor, John P Sabo, Stephen H Norris, et al.
HIV Clinical Trials
|
February 20, 2016
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Nicolas A Margot, Kathryn M Kitrinos, Marshall Fordyce, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2004
A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
Scott McCallister, Hernan Valdez, Kevin Curry, et al.
HIV Clinical Trials
|
April 20, 2010
Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients
Frank D Goebel, Thomas R MacGregor, John P Sabo, et al.
Antimicrobial Agents and Chemotherapy
|
November 24, 2005
Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers
Geoffrey Mukwaya, Thomas MacGregor, David Hoelscher, et al.
Plos One
|
December 12, 2019
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
Linn Hermansson, Aylin Yilmaz, Richard W Price, et al.
Page
of 4